Skip to content

Integra LifeSciences Confirms Earnings Guidance


<< Back

Press Release

Mar 26, 2003

Integra LifeSciences Confirms Earnings Guidance

Integra LifeSciences Confirms Earnings Guidance Plainsboro, NJ / March 26, 2003 / -- Integra LifeSciences Holdings Corporation (NASDAQ: IART - news) announced today that the Company's guidance for earnings per share of $0.16 for the first quarter of 2003 remains unchanged. Excluding a potential in-process research and development charge related to a $1.5 million milestone payment that may become due in connection with a previous acquisition, we expect our earnings to be within a range of $0.78 to $0.82 per share in 2003 and $1.05 to $1.10 per share in 2004. In accordance with the Company's usual practices, management's expectations for 2003 and 2004 financial performance do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed. Additional forward-looking information will be discussed on Integra's conference call following the release of our first quarter 2003 earnings on April 30, 2003.

Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, instruments, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 860 regular employees. Please visit the Company's Website at (http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning expectations for future financial results, including revenues, gross margins and earnings. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's ability to maintain relationships with customers of acquired entities may adversely affect Integra's future revenues; Integra's ability to increase sales and product volumes may adversely affect its future gross margins; and Integra'a ability to integrate acquired businesses, increase product sales and gross margins, and control its nonproduct costs will affect its earnings per share. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2002 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation

Contacts:
Integra LifeSciences Holdings Corporation
John B. Henneman, III John Bostjancic
Executive Vice President Senior Director of Finance
Chief Administrative Officer (609) 936-2239
(609) 936-2481 jbostjancic@integra-ls.com
jhenneman@integra-ls.com